Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:57 PM
Ignite Modification Date:
2025-12-24 @ 3:57 PM
NCT ID:
NCT06616792
Eligibility Criteria:
Inclusion Criteria:
* Age range between 30 to 50 years.
* Male and female patients will participate in the study.
* All patients have chronic rhinosinusitis, who are experiencing 12 weeks or longer of 2 or more of the following signs and symptoms:
mucopurulent drainage (anterior, posterior, or both) nasal obstruction (congestion) facial pain-pressure-fullness, or decreased sense of smell
• All patients enrolled in the study will have their informed consent.
Exclusion Criteria:
* Patients with metal implants (pacemakers, dental implants, or any other implants).
* Patients with cancer, pregnancy or impaired vascular circulation.
* Patients who suffer from mental or psychological disorders.
* Patients with any systemic diseases that may interfere with the objectives of the study.
* Patients with long-term use of corticosteroids or immunosuppressive agents.
* Congenital defects on face and nose.
* Fracture of nose or face.
* Patients who are contraindicated for corticosteroids use in patient who will receive dexamethasone phonophoresis.
* Allergic patients.
* Pervious nasal surgery.
* Patients with nasal septum deviation.
* patients who had used antihistamines within 1 week, topical corticosteroids within2 weeks, systemic corticosteroids within 4 weeks, anti-cholinergic drugs within 3 days, antileukotriene drugs within 1 week, decongestants within 3 days, tricyclic antidepressants or phenothiazines within 2 weeks, non-steroidal analgesics within 2 weeks or any medication that may interfere with the objectives of the study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
30 Years
Maximum Age:
50 Years
Study:
NCT06616792
Study Brief:
Protocol Section:
NCT06616792